{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T23:01:32Z","timestamp":1770073292232,"version":"3.49.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The direct effects of adenosine A1 receptor antagonists on haemodynamic parameters in patients with acute heart failure (HF) remain largely unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We evaluated the haemodynamic effects of the AA1RA rolofylline in 59 HF patients with concomitant renal impairment (estimated creatinine clearance 20\u201380 mL\/min). Placebo or rolofylline 30 mg was administered as a 4 h infusion followed by intravenous (i.v.) loop diuretic administration. Haemodynamic measurements were carried out hourly up to 8 h post-dosing by pulmonary artery catheterization. Urine output, fractional excretion of sodium, potassium, urea, and uric acid, and blood urea nitrogen (BUN) and creatinine levels were also measured. In both groups, the changes from baseline in all haemodynamic indices except mean pulmonary artery pressure (PAP) were not clinically significant. Mean [95% confidence interval (CI)] PAP showed a placebo-adjusted decrease with rolofylline of \u22121.5 (\u22124.1, 1.1)mmHg at Hour 4 and \u22123.5 mmHg (95% CI: \u22126.2, \u22120.2) at Hour 8. There was a significant increase with rolofylline in diuresis [placebo-corrected mean (95% CI) change of 68 (20, 116)mL\/h at Hour 2\u20134 and 103 (21, 185)mL\/h at Hour 4\u20138] and in fractional excretion of sodium, potassium, and uric acid. Placebo-corrected changes in plasma levels of creatinine and BUN with rolofylline were non-significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Single administration of rolofylline in patients with HF and impaired renal function produced a slight decrease in mean PAP and consistently increased diuresis and natriuresis without compromising renal function, both before and after administration of i.v. loop diuretics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjhf\/hfq137","type":"journal-article","created":{"date-parts":[[2010,9,7]],"date-time":"2010-09-07T21:06:13Z","timestamp":1283893573000},"page":"1238-1246","source":"Crossref","is-referenced-by-count":15,"title":["Haemodynamic Effects of Rolofylline in the Treatment of Patients with Heart Failure and Impaired Renal Function"],"prefix":"10.1093","volume":"12","author":[{"given":"Piotr","family":"Ponikowski","sequence":"first","affiliation":[{"name":"Department of Heart Diseases, Medical University, Clinical Military Hospital , Weigla 5, 50-891, Wroclaw ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veselin","family":"Mitrovic","sequence":"additional","affiliation":[{"name":"Kerckhoff-Klinik , Bad Nauheim ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"O'Connor","sequence":"additional","affiliation":[{"name":"Duke University Medical Center , Durham, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Dittrich","sequence":"additional","affiliation":[{"name":"NovaCardia , San Diego, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gad","family":"Cotter","sequence":"additional","affiliation":[{"name":"Momentum Research , Durham, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry M.","family":"Massie","sequence":"additional","affiliation":[{"name":"San Francisco VAMC , San Francisco, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael M.","family":"Givertz","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erluo","family":"Chen","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Upper Gwynedd, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith","family":"Murray","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Upper Gwynedd, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth D.","family":"Weatherley","sequence":"additional","affiliation":[{"name":"Momentum Research , Durham, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji P.","family":"Fujita","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Cardiology Division, Department of Experimental and Applied Medicine, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,1,13]]},"reference":[{"key":"2026020203344460400_ejhfhfq137-bib-0001","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cardfail.2007.03.011","article-title":"High prevalence of renal dysfunction and its impact on outcome in patients hospitalized with acute decompensated heart failure: a report from the ADHERE database","volume":"13","author":"Heywood","year":"2007","journal-title":"J Card Fail"},{"key":"2026020203344460400_ejhfhfq137-bib-0002","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejheart.2008.01.011","article-title":"Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance","volume":"10","author":"Metra","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026020203344460400_ejhfhfq137-bib-0003","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.cardfail.2007.04.008","article-title":"Worsening renal function and prognosis in heart failure: systematic review and meta-analysis","volume":"13","author":"Damman","year":"2007","journal-title":"J Card Fail"},{"key":"2026020203344460400_ejhfhfq137-bib-0004","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0735-1097(99)00608-7","article-title":"The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction","volume":"35","author":"Dries","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026020203344460400_ejhfhfq137-bib-0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2165\/00003495-199000394-00004","article-title":"Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function","volume":"39","author":"Ljungman","year":"1990","journal-title":"Drugs"},{"key":"2026020203344460400_ejhfhfq137-bib-0006","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jacc.2007.09.043","article-title":"Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function?","volume":"51","author":"Mullens","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026020203344460400_ejhfhfq137-bib-0007","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2008.05.068","article-title":"Importance of venous congestion for worsening of renal function in advanced decompensated heart failure","volume":"53","author":"Mullens","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026020203344460400_ejhfhfq137-bib-0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-103-1-1","article-title":"Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis","volume":"103","author":"Francis","year":"1985","journal-title":"Ann Intern Med"},{"key":"2026020203344460400_ejhfhfq137-bib-0009","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.amjcard.2005.12.072","article-title":"Relation of loop diuretic dose to mortality in advanced heart failure","volume":"97","author":"Eshaghian","year":"2006","journal-title":"Am J Cardiol"},{"key":"2026020203344460400_ejhfhfq137-bib-0010","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1152\/physrev.00031.2005","article-title":"Adenosine and kidney function","volume":"86","author":"Vallon","year":"2006","journal-title":"Physiol Rev"},{"key":"2026020203344460400_ejhfhfq137-bib-0011","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0735-1097(99)00532-X","article-title":"Effects of BG9719 (CVT-124), an A1 adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure","volume":"35","author":"Gottlieb","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026020203344460400_ejhfhfq137-bib-0012","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1161\/hc1102.105264","article-title":"BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy","volume":"105","author":"Gottlieb","year":"2002","journal-title":"Circulation"},{"key":"2026020203344460400_ejhfhfq137-bib-0013","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jacc.2007.03.059","article-title":"Effects of multiple oral doses of an A1 adenosine antagonist BG9928 in patients with heart failure. Results of a placebo-controlled dose escalation study","volume":"50","author":"Greenberg","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026020203344460400_ejhfhfq137-bib-0014","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cardfail.2007.08.006","article-title":"The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment","volume":"13","author":"Dittrich","year":"2007","journal-title":"J Card Fail"},{"key":"2026020203344460400_ejhfhfq137-bib-0015","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.jacc.2007.07.019","article-title":"The effects of KW-3902, an adenosine a1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance","volume":"50","author":"Givertz","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026020203344460400_ejhfhfq137-bib-0016","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.cardfail.2008.08.010","article-title":"The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment","volume":"14","author":"Cotter","year":"2008","journal-title":"J Cardiac Fail"},{"key":"2026020203344460400_ejhfhfq137-bib-0017","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/CIRCHEARTFAILURE.108.798389","article-title":"Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure","volume":"2","author":"Mitrovic","year":"2009","journal-title":"Circ Heart Fail"},{"key":"2026020203344460400_ejhfhfq137-bib-0018","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cardfail.2009.10.025","article-title":"Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function","volume":"16","author":"Dittrich","year":"2010","journal-title":"J Cardiac Fail"},{"key":"2026020203344460400_ejhfhfq137-bib-0019","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"2026020203344460400_ejhfhfq137-bib-0020","first-page":"1531","article-title":"Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure","volume":"287","author":"Publications Committee for the VMAC Investigators","year":"2002","journal-title":"JAMA"},{"key":"2026020203344460400_ejhfhfq137-bib-0021","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ejheart.2004.05.004","article-title":"The hemodynamic and neurohumoral effects of low dose of tezosentan (an endothelin A\/B receptor antagonist) in patients with acute heart failure","volume":"6","author":"Cotter","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"2026020203344460400_ejhfhfq137-bib-0022","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/hrt.36.1.44","article-title":"Haemodynamic effects of frusemide in patients suspected of having acute myocardial infarction","volume":"36","author":"Mond","year":"1974","journal-title":"Br Heart J"},{"issue":"Suppl. 2","key":"2026020203344460400_ejhfhfq137-bib-0023","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1136\/hrt.72.2_Suppl.S44","article-title":"Haemodynamic effects of diuretics in heart failure","volume":"72","author":"Raftery","year":"1994","journal-title":"Br Heart J"},{"key":"2026020203344460400_ejhfhfq137-bib-0024","first-page":"125","article-title":"Comparison of pulmonary wedge pressure with left ventricular end-diastolic pressure in man","volume":"34","author":"Sapru","year":"1968","journal-title":"Clin Sci"},{"key":"2026020203344460400_ejhfhfq137-bib-0025","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/hrt.33.4.494","article-title":"Relations between pressure in pulmonary artery, left atrium, and left ventricle with special reference to events at end diastole","volume":"33","author":"Forsberg","year":"1971","journal-title":"Br Heart J"},{"key":"2026020203344460400_ejhfhfq137-bib-0026","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/cvr\/6.2.172","article-title":"Comparison of pulmonary-artery diastolic and left ventricular end diastolic pressures in patients with ischemic-heart disease","volume":"6","author":"Balcon","year":"1972","journal-title":"Card Res"},{"key":"2026020203344460400_ejhfhfq137-bib-0027","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/oxfordjournals.eurheartj.a059508","article-title":"Treatment of heart failure with diuretics: body compartments, renal function and plasma hormones","volume":"10","author":"Anand","year":"1989","journal-title":"Eur Heart J"},{"key":"2026020203344460400_ejhfhfq137-bib-0028","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1161\/hc4501.099313","article-title":"Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure","volume":"104","author":"Udelson","year":"2001","journal-title":"Circulation"},{"key":"2026020203344460400_ejhfhfq137-bib-0029","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.jacc.2008.08.013","article-title":"Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial","volume":"52","author":"Udelson","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026020203344460400_ejhfhfq137-bib-0030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10741-008-9127-5","article-title":"Vasodilators in the treatment of acute heart failure: what we know, what we don't","volume":"14","author":"Metra","year":"2009","journal-title":"Heart Fail Rev"},{"key":"2026020203344460400_ejhfhfq137-bib-0031","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1067\/mhj.2001.115299","article-title":"Hemodynamics as surrogate end points for survival in advanced heart failure: an analysis from FIRST","volume":"141","author":"Shah","year":"2001","journal-title":"Am Heart J"},{"key":"2026020203344460400_ejhfhfq137-bib-0032","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"2026020203344460400_ejhfhfq137-bib-0033","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/eurheartj\/ehn048","article-title":"A proposal to standardize dyspnea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach","volume":"29","author":"Pang","year":"2008","journal-title":"Eur Heart J"},{"key":"2026020203344460400_ejhfhfq137-bib-0034","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0022-3565(25)32898-3","article-title":"Sedative and anticonvulsant effects of adenosine analogs in mouse and rat","volume":"220","author":"Dunwiddie","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"2026020203344460400_ejhfhfq137-bib-0035","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/0091-3057(90)90072-P","article-title":"Adenosine receptor antagonism accounts for seizure prolonging effects of aminophylline","volume":"36","author":"Dragunow","year":"1990","journal-title":"Pharmacol Biochem Behav"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfq137","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/12\/11\/1238\/66522540\/eurjhf_12_11_1238.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/12\/11\/1238\/66522540\/eurjhf_12_11_1238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:34:53Z","timestamp":1770021293000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/12\/11\/1238\/8435900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,1]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2014,1,13]]},"published-print":{"date-parts":[[2010,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjhf\/hfq137","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,11]]},"published":{"date-parts":[[2010,11,1]]}}}